Glecaprevir PK Fact Sheet

**Details**

**Generic Name**  
Glecaprevir

**Trade Name**  
Maviret®, Mavyret®, (co-formulated with pibrentasvir)

**Class**  
HCV NS3/4A inhibitor

**Molecular Weight**  
838.87

**Structure**

![Structure of Glecaprevir](image)

### Summary of Key Pharmacokinetic Parameters

Glecaprevir is available in a fixed-dose combination product with pibrentasvir.

**Linearity/non-linearity**  
Glecaprevir AUC increases in a greater than dose-proportional manner (1200 mg once daily had 516-fold higher exposure than 200 mg once daily) which may be related to saturation of uptake and efflux transporters

**Steady state**  
Achieved after 7 days of once daily dosing

**Plasma half-life**  
6-9 h

**Cmax**  
597 (114) ng/mL (geometric mean, %CV), in non-cirrhotic HCV-infected subjects

**C24**  
3.07 (54), 5.50 (46), 3.72 (71) ng/mL (geometric mean, %CV), in healthy White, Han Chinese and Japanese adults, respectively

**AUC**  
4800 (122) ng∙h/mL (geometric mean, %CV), in non-cirrhotic HCV-infected subjects

**Bioavailability**  
Not reported

**Absorption**  
Compared to fasting, a moderate to high-fat meal increased glecaprevir exposure by 83-163%

**Protein Binding**  
97.5%

**Volume of Distribution**  
Not reported

**CSF:Plasma ratio**  
Not reported

**Semen:Plasma ratio**  
Not reported

**Renal Clearance**  
0.7% of dose excreted in urine

**Renal Impairment**  
No dosage adjustment is required in patients with mild, moderate or severe renal impairment, including those on dialysis.

**Hepatic Impairment**  
No dose adjustment is required in patients with mild hepatic impairment (Child-Pugh A). Glecaprevir is not recommended in patients with moderate hepatic impairment (Child-Pugh B) and is contraindicated in patients with severe hepatic impairment (Child-Pugh C).
**Glecaprevir PK Fact Sheet**

### Metabolism and Distribution

**Metabolised by**

CYP3A (minimal) – glecaprevir is mainly eliminated by biliary/faecal excretion

**Inducer of**

None expected

**Inhibitor of**

Inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, BSEP.  
Weak inhibitor of CYP3A, CYP1A2, UGT1A1 (significant interactions are not expected with substrates of these enzymes). 
Significant inhibition of CYP2C9, CYP2C19, CYP2D6, UGT1A6, UGT1A9, UGT1A4, UGT2B7, OCT1, OCT2, OAT1, OAT3, MATE1 or MATE2K are not expected.

**Transported by**

P-gp, BCRP, OATP1B1, OATP1B3

### References

Unless otherwise stated (see below), information is from:  
Maviret Summary of Product Characteristics, AbbVie Ltd.  
Mavyret Prescribing Information, AbbVie Inc.
